Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Vaccine regulations in Croatia.

Kaić B, Gjenero-Margan I, Brzović M, Lakoseljac D, Aleraj B, Nemeth-Blazić T, Kolarić B, Macolić-Sarinić V, Simunović A, Pavlić J.

Coll Antropol. 2007 Apr;31 Suppl 2:117-20.

PMID:
17598513
2.

Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The Netherlands.

Boot HJ, Wallenburg I, de Melker HE, Mangen MJ, Gerritsen AA, van der Maas NA, Berkhof J, Meijer CJ, Kimman TG.

Vaccine. 2007 Aug 14;25(33):6245-56. Epub 2007 Jun 21.

PMID:
17630049
3.

Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium.

Annemans L, Rémy V, Oyee J, Largeron N.

Pharmacoeconomics. 2009;27(3):231-45. doi: 10.2165/00019053-200927030-00006.

PMID:
19354343
4.

Human papillomavirus vaccine: a paradigm shift for pediatricians.

Jenson HB.

Curr Opin Pediatr. 2009 Feb;21(1):112-21. doi: 10.1097/MOP.0b013e3283207f93. Review.

PMID:
19242247
5.

Human papillomavirus vaccine: recommendations, issues and controversies.

Fisher R, Darrow DH, Tranter M, Williams JV.

Curr Opin Pediatr. 2008 Aug;20(4):441-5. doi: 10.1097/MOP.0b013e328305e298. Review.

PMID:
18622201
6.

Human papillomavirus vaccine recommendations and agreement with mandated human papillomavirus vaccination for 11-to-12-year-old girls: a statewide survey of Texas physicians.

Kahn JA, Cooper HP, Vadaparampil ST, Pence BC, Weinberg AD, LoCoco SJ, Rosenthal SL.

Cancer Epidemiol Biomarkers Prev. 2009 Aug;18(8):2325-32. doi: 10.1158/1055-9965.EPI-09-0184.

7.

Preventing cervical cancer through human papillomavirus vaccination: perspective from focus groups.

Wong LP.

J Low Genit Tract Dis. 2009 Apr;13(2):85-93. doi: 10.1097/LGT.0b013e3181865f44.

PMID:
19387128
8.

Human papillomavirus vaccine policy and delivery in Latin America and the Caribbean.

Andrus JK, Lewis MJ, Goldie SJ, García PJ, Winkler JL, Ruiz-Matus C, de Quadros CA.

Vaccine. 2008 Aug 19;26 Suppl 11:L80-7. doi: 10.1016/j.vaccine.2008.05.040. Review.

PMID:
18945405
9.

A review of prophylactic human papillomavirus vaccines: recommendations and monitoring in the US.

Dunne EF, Datta SD, E Markowitz L.

Cancer. 2008 Nov 15;113(10 Suppl):2995-3003. doi: 10.1002/cncr.23763. Review.

10.

[Vaccines against human papillomavirus (HPV); between registration and implementation].

van Rossum TG, de Melker HE, Houweling H, Voordouw AC, Meijer CJ, Helmerhorst TJ, Kretzschmar M, Berkhof J, van der Noordaa J.

Ned Tijdschr Geneeskd. 2008 Apr 26;152(17):987-92. Review. Dutch.

PMID:
18549172
11.

The HPV vaccine: framing the arguments FOR and AGAINST mandatory vaccination of all middle school girls.

Vamos CA, McDermott RJ, Daley EM.

J Sch Health. 2008 Jun;78(6):302-9. doi: 10.1111/j.1746-1561.2008.00306.x.

PMID:
18489462
12.

[Insufficient basis for the inclusion of Human papillomavirus vaccination in the National Immunisation Programme in The Netherlands].

de Kok IM, Habbema JD, Mourits MJ, Coebergh JW, van Leeuwen FE.

Ned Tijdschr Geneeskd. 2008 Sep 13;152(37):2001-4. Dutch.

PMID:
18825885
13.

The HPV vaccine mandate controversy.

Haber G, Malow RM, Zimet GD.

J Pediatr Adolesc Gynecol. 2007 Dec;20(6):325-31. Review.

PMID:
18082853
14.

Effectiveness and cost effectiveness of human papillomavirus vaccine: a systematic review.

Marra F, Cloutier K, Oteng B, Marra C, Ogilvie G.

Pharmacoeconomics. 2009;27(2):127-47. doi: 10.2165/00019053-200927020-00004. Review. Erratum in: Pharmacoeconomics. 2009;27(4):354.

PMID:
19254046
15.

Assessing mandatory HPV vaccination: who should call the shots?

Javitt G, Berkowitz D, Gostin LO.

J Law Med Ethics. 2008 Summer;36(2):384-95, 214. doi: 10.1111/j.1748-720X.2008.00282.x. Review.

PMID:
18547207
16.
17.

Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland.

Szucs TD, Largeron N, Dedes KJ, Rafia R, Bénard S.

Curr Med Res Opin. 2008 May;24(5):1473-83. doi: 10.1185/030079908X297826 . Epub 2008 Apr 14.

PMID:
18413014
18.

A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program.

Kulasingam S, Connelly L, Conway E, Hocking JS, Myers E, Regan DG, Roder D, Ross J, Wain G.

Sex Health. 2007 Sep;4(3):165-75.

PMID:
17931529
19.

Human papillomavirus vaccine legislation in Kentucky: a policy analysis.

Dekker RL.

Policy Polit Nurs Pract. 2008 Feb;9(1):40-9. doi: 10.1177/1527154408317851. Review.

PMID:
18492941
20.

Cost-effectiveness of prophylactic vaccination against human papillomavirus 16/18 for the prevention of cervical cancer: adaptation of an existing cohort model to the situation in the Netherlands.

Rogoza RM, Westra TA, Ferko N, Tamminga JJ, Drummond MF, Daemen T, Wilschut JC, Postma MJ.

Vaccine. 2009 Jul 30;27(35):4776-83. doi: 10.1016/j.vaccine.2009.05.085. Epub 2009 Jun 17.

PMID:
19539578
Items per page

Supplemental Content

Write to the Help Desk